Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The disclosure states that Panmure Gordon (UK) Limited, as an exempt principal trader, has made purchases and sales of Allergy Therapeutics' 0.1p ordinary shares. The purchases involved 100,000 securities at a highest price per unit of 0.014p and a lowest price per unit of 0.014p. The sales involved 165,226 securities at a highest price per unit of 0.0154p and a lowest price per unit of 0.015p.

The disclosure does not mention any cash-settled derivative transactions or stock-settled derivative transactions related to Allergy Therapeutics' securities. It also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities between Panmure Gordon (UK) Limited and any other party. The disclosure was made on October 4, 2023, and the contact person for further information is Freddie Wooding at +44 (0)20 7886 2969.

No further information about Allergy Therapeutics or its operations is provided in this news release.